EP Patent

EP2695609A1 — Oral formulations of cytidine analogs and methods of use thereof

Assigned to Celgene Corp · Expires 2014-02-12 · 12y expired

What this patent protects

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulat…

USPTO Abstract

The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP2695609A1
Jurisdiction
EP
Classification
—
Expires
2014-02-12
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.